Broadcasting at 8:30 a.m. EDT.
NCI Director Dr. Ned Sharpless will participate in a panel discussion with ASCO leaders Cliff Hudis, MD, and Skip Burris, MD. Dr. Sharpless will explain the flexibilities NCI granted to clinical trials during the COVID-19 pandemic and highlight how the lessons learned will support future cancer research and effective patient care.
|
NCI program director Dr. Tony Dickherber will present “The Emerging Liquid Biopsy Technology Landscape.” Dr. Dickherber will discuss the commercial landscape for available platforms and approaches, persistent technical challenges that hamper their adoption, and emerging technologies that NCI has supported to address those challenges. In addition, he will discuss the important role clinician-scientists can and should play in accelerating the incorporation of liquid biopsies into clinical trials with sarcoma patients.
|
Dr. Stephanie Goff, Associate Research Physician in NCI’s Surgery Branch will present “Killer T’s: the History and Future of Cell Therapy.” Dr. Goff’s presentation will discuss cell-based immunotherapy for the treatment of metastatic melanoma, starting from the earliest studies of lymphokine-activated killer cells in 1985 to the latest studies of tumor infiltrating lymphocytes (TIL) for clinical treatment and neoantigen exploration for future T-cell receptor (TCR) gene-engineered cells.
|
Visit our NCI at ASCO page for resources, funding opportunities, and more information on NCI's presence at ASCO's Virtual Education Program, or find us in the ASCO20 Virtual Exhibit Hall!
To join the discussion, follow NCI on Twitter at @theNCI and Instagram at @nationalcancerinstitute.
|
No hay comentarios:
Publicar un comentario